Back to top
more

Emergent Biosolutions (EBS)

(Delayed Data from NYSE)

$5.63 USD

5.63
1,474,748

-0.25 (-4.25%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $5.63 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Maharathi Basu headshot

5 Broker-Loved Stocks Amid EU Tariff Pause & Consumer Confidence Boost

by Maharathi Basu

Broker-favored picks like BYON, BTSG, ACDVF, EBS, and ADNT are worth monitoring amid EU tariff delay and rising consumer confidence.

Zacks Equity Research

Zacks.com featured highlights include BrightSpring Health Services, Beyond, Air Canada, HF Sinclair and Emergent BioSolutions

by Zacks Equity Research

BrightSpring Health Services, Beyond, Air Canada, HF Sinclair and Emergent BioSolutions are part of the Zacks Screen of the Week article.

Maharathi Basu headshot

5 Broker-Loved Stocks to Watch Amid Signs of Easing Trade Woes

by Maharathi Basu

Investors would do well to monitor broker-favored stocks like BTSG, BYON, ACDVF, DINO, and EBS for high returns.

Zacks Equity Research

Emergent Biosolutions (EBS) Q1 Earnings Top Estimates

by Zacks Equity Research

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 44.90% and 2.82%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last?

by Zacks Equity Research

Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Sundeep Ganoria headshot

JAZZ Pharmaceuticals Stock Trades Near 52-Week Low: Time to Buy or Sell?

by Sundeep Ganoria

We advise investors to use the price dip in JAZZ stock as a buying opportunity despite the dynamic shifts in the regulatory landscape.

Zacks Equity Research

Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio

by Zacks Equity Research

JAZZ's acquisition of CMRX is set to add a rare high-grade brain tumor drug currently under the FDA's review. The deal is likely to be closed by June 2024.

Zacks Equity Research

Emergent Biosolutions (EBS) Q4 Earnings Top Estimates

by Zacks Equity Research

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 114.29% and 22.93%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Gilead Sciences (GILD) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Gilead (GILD) delivered earnings and revenue surprises of 13.77% and 7.27%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Bristol Myers Squibb (BMY) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Bristol Myers (BMY) delivered earnings and revenue surprises of 14.38% and 6.59%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Sundeep Ganoria headshot

Emergent Stock Skyrockets 251% YTD: How to Play the Stock?

by Sundeep Ganoria

The appointment of CEO John Papa earlier this year has been a key driver of EBS' strong performance, sparking significant investor optimism.

Zacks Equity Research

New Strong Buy Stocks for November 7th

by Zacks Equity Research

MCO, EBS, LIVN, FTDR and KRUS have been added to the Zacks Rank #1 (Strong Buy) List on November 7, 2024.

Zacks Equity Research

Emergent Biosolutions (EBS) Q3 Earnings Beat Estimates

by Zacks Equity Research

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 179.59% and 10.62%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of -43.75% and 1.04%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zacks.com featured highlights include American Airlines, Air Canada, EmergentBioSolutions, Berry and Cracker Barrel Old Country Store

by Zacks Equity Research

American Airlines, Air Canada, EmergentBioSolutions, Berry and Cracker Barrel Old Country Store have been highlighted in this Screen of The Week article.

Maharathi Basu headshot

5 Broker Liked Stocks to Keep an Eye on After Recent Analyst Upgrades

by Maharathi Basu

Investors should monitor stocks like AAL, ACDVF, EBS, BRY and CBRL for high returns.

Zacks Equity Research

Zacks.com featured highlights include Grupo Supervielle, Emergent BioSolutions and Innodata

by Zacks Equity Research

Grupo Supervielle, Emergent BioSolutions and Innodata are part of the Zacks Screen of the Week article.

Shrabana Mukherjee headshot

3 Stocks Poised for Better Returns With New Analyst Coverage

by Shrabana Mukherjee

The recent surge in analyst coverage for stocks such as SUPV, EBS and INOD indicates the potential for significant price appreciation in the near term.

Zacks Equity Research

Should Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for PRFZ

Zacks Equity Research

EBS Stock Rises on FDA Nod for ACAM2000 in Mpox Indication

by Zacks Equity Research

The FDA approves Emergent BioSolutions' sBLA seeking a label expansion of ACAM2000 for the mpox indication. Stock rises in pre-market trading.

Zacks Equity Research

Zacks Investment Ideas feature highlights: Virax Biolabs Group, GeoVax Labs, Applied DNA Sciences and Emergent BioSolutions

by Zacks Equity Research

Virax Biolabs Group, GeoVax Labs, Applied DNA Sciences and Emergent BioSolutions have been highlighted in this Investment Ideas article.

Andrew Rocco headshot

WHO Declares Monkeypox Public Emergency: 5 Mpox Stocks to Watch

by Andrew Rocco

Is the next pandemic here. With health officials declaring Monkeypox a public health emergency, investors need to be watching Monkeypox-related stocks.

Zacks Equity Research

Repligen (RGEN) Q2 Earnings Meet Estimates

by Zacks Equity Research

Repligen (RGEN) delivered earnings and revenue surprises of 0% and 0.16%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Myriad (MYGN) Down 5.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Axsome (AXSM) Down 6.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.